Background and Aims
Since the introduction of direct oral anticoagulant (DOAC) for atrial fibrillation (AF) therapy, inappropriate and/or underdosing of these drugs has been a major clinical challenge. We evaluated the characteristics of AF patients treated with inappropriate and low dose DOACs.
Methods
AF patients treated with inappropriate and low dose DOACs from October 2021 to December 2021 were evaluated from the Prospective French National Registry (PAF).
Results
We evaluated 1890 AF patients receiving DOACs (Apixaban 55%, Dabigatran 7% and Rivaroxaban 38%). Inappropriate dosing was noted in 18% of the population. Patients with appropriate dosing had less comorbidities: younger age (75±10 vs. 82±8 year-old, p<0.0001), reduced chronic renal failure (26% vs. 61%, p<0.0001) and lower CHA2DS2VASc and HASBLED scores (3±2 vs. 4±3, p<0.0001; 2±1 vs. 2±2, p<0.0001), respectively. In multivariate analysis older age (p<0.0001) and a higher CHA2DS2VASc score (p=0.0056) were independently associated with inappropriate DOAC dosing. Among 472 patients (27%) treated with low dose rivaroxaban or apixaban, 46% were inappropriately underdosed. Patients inappropriately underdosed were younger (82.3±8.4 vs. 85.9±5.9 yrs, p<0.0001) with less chronic renal disease (47% vs. 98%, p<0.0001). However, these patients had higher rates of prior haemorrhagic events (18% vs. 10%, p=0.01), clopidogrel use (11% vs. 3%, p=0.0002) and apixaban prescription (74% vs. 50%, p<0.0001).
Conclusion
Within this large registry, DOACs were associated with inappropriate dosing in 18% of cases. Independent predictors of inappropriate dosing were high CHA2DS2VASc scores and older age. Moreover, 46% of patients treated with low dose DOACs were inappropriately underdosed and more frequently occurred with apixaban.